Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: garrido cano i. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gúrpide J, Burgués O, Hernando C, Bermejo B, Martínez MT, Lluch A, Cejalvo JM, Eroles P. Torres-Ruiz S, et al. Among authors: garrido cano i. Int J Mol Sci. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. Int J Mol Sci. 2023. PMID: 36835014 Free PMC article.
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gúrpide J, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Cancer Commun (Lond). 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. Epub 2022 Aug 23. Cancer Commun (Lond). 2022. PMID: 35997029 Free PMC article. No abstract available.
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Garrido-Cano I, et al. Cancer Metastasis Rev. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. Epub 2021 Sep 15. Cancer Metastasis Rev. 2022. PMID: 34524579 Free PMC article. Review.
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.
Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, Lameirinhas A, Simón S, Ortega-Morillo B, Martínez MT, Hernando C, Constâncio V, Burgues O, Bermejo B, Henrique R, Lluch A, Jerónimo C, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: garrido cano i. Cancers (Basel). 2021 Jun 7;13(11):2848. doi: 10.3390/cancers13112848. Cancers (Basel). 2021. PMID: 34200463 Free PMC article.
14 results